|
A Pilot Trial of Phenylbutyrate/Genistein Duotherapy (for Cystic Fibrosis) Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified medical advice, visits or professional assistance with a genuine dr.. We are not doctors. Always consult your mD about A Pilot Trial of Phenylbutyrate/Genistein Duotherapy (for Cystic Fibrosis) conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. A Pilot Trial of Phenylbutyrate/Genistein Duotherapy (for Cystic Fibrosis) Clinical research trials and A Pilot Trial of Phenylbutyrate/Genistein Duotherapy (for Cystic Fibrosis) medical trials take place in many of places throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the effectiveness of new does drugs. The purpose of the studies / projects is to solve specific human healthcare questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to find cures for all varieties of conditions, like A Pilot Trial of Phenylbutyrate/Genistein Duotherapy (for Cystic Fibrosis). A Pilot Trial of Phenylbutyrate/Genistein Duotherapy (for Cystic Fibrosis) Clinical Trials and other clinical trials allow for volunteers to have health treatment options before they are available to the masses. Many times the human subjects acquire professional assistance for free of charge, and sometimes they are compensated for their time. Occasionally there is a cost for a A Pilot Trial of Phenylbutyrate/Genistein Duotherapy (for Cystic Fibrosis) clinical trial. Test subjects typically obtain the finest healthcare available for their A Pilot Trial of Phenylbutyrate/Genistein Duotherapy (for Cystic Fibrosis) condition. Dangers are a reality, nevertheless, and might include additional or frequent doctor trips, medical dangers (possibly life-jeopardising), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A Pilot Trial of Phenylbutyrate/Genistein Duotherapy (for Cystic Fibrosis)  A Pilot Trial of Phenylbutyrate/Genistein Duotherapy (for Cystic Fibrosis)
A Pilot Trial of Phenylbutyrate/Genistein Duotherapy (for Cystic Fibrosis)
For Condition: Cystic Fibrosis
Status: Recruiting
Sponsor(s): National Center for Research Resources (NCRR) , Cystic Fibrosis Foundation Therapeutics
Synopsis: We are testing a new combination of medicines, to determine if they could be used to treat cystic fibrosis (CF). Subjects with CF who have two copies of the most common mutation (change) found in patients with CF called DF508. CF is caused by a lack of chloride movement in the nose, sinuses, lungs, intestines, pancreas and sweat glands. We are conducting this study to determine the safety of using a combination of two medicines, Phenylbutyrate and Genistein, to improve the ability of the cells lining the nose to regulate movement of salt (chloride) and water in people with CF. Phenylbutyrate has been extensively used to treat patients with rare metabolic diseases (which are very different from CF), Phenylbutyrate is an investigational drug for the purpose of this study. Genistein is a naturally occurring substance that is found in food products such as soy and tofu, but is also an investigational drug for this study. Both drugs may be able to restore normal chloride movements in body organs and glands. We will be studying salt and water in the nose movement by a technique called nasal transepithelial potential difference (NPD).
Details: Subjects will be randomized to receive either the Phenylbutyrate or placebo tablets for 1 week, with a 2 out of 3 chance of receiving Phenylbutyrate at a standard adult dose, with visits on study days 1, 4, and 7. The study will last an additional 2 weeks to determine whether the effects of the Phenylbutyrate or Placebo persist for any length of time, with visits on study days 14 and 21. Every participant will receive the Genistein during the NPD on days 1 and 7. The dose of Genistein used will not be escalated and will be the same for every participant. Safety evaluations at each visit will include a history, and physical exam and mental status exam, blood and urine tests, and lung function tests. The main physiologic outcome of the trial will be the assessment of salt and water transport NPD. In this way, we will assess whether genistein enhances the effect of phenylbutyrate to improve chloride transport in the nose by topical application of genistein to the nasal mucosa during the NPD procedure on study days 1 and 7.
Eligibility:
Study Type: Interventional, Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: a) All ethnic groups b) Females and males c) 18 years of age or older d) Able to communicate with pertinent staff, able to understand and willing to comply with the requirements of the trial, and able and willing to give informed consent. e) Willing to practice a reliable and study-accepted method of contraception during the study Acceptable methods are abstinence, barrier methods, or oral contraceptives. (This is predominantly directed at female subjects, as males with CF are typically sterile due to obstructive azospermia. We will encourage males to use barrier methods for the duration of the study on the small chance that fertility exists). f) Diagnosis of cystic fibrosis consisting of both: - sweat sodium or chloride > 60 mEq/L by the pilocarpine iontophoresis method and cystic fibrosis genotype homozygous for DF508-CFTR - clinical manifestations of cystic fibrosis h) Oxyhemoglobin saturation ? 92% while breathing room air
Total Enrollment:
Location and Contact Information:
Children's Hospital of Philadelphia *Recruiting*
Philadelphia, Pennsylvania, 19101
United States
Recruiting Ronald Rubenstein 215-590-1281
Additional Information:
Study ID Numbers: NCRR-M01RR00240-1765;
Study Start Date:
Record last reviewed: December 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00016744
Other Cystic Fibrosis Studies:
1. Phase II Study of Growth Hormone in Children With Cystic Fibrosis
2. Pressure support ventilation during CF exacerbations
3. Phase I Pilot Study of Ad5-CB-CFTR, an Adenovirus Vector Containing the Cystic Fibrosis Transmembrane Conductance Regulator Gene, in Patients with Cystic Fibrosis
4. Tissue Collection from People with Cystic Fibrosis
5. Quantification of pulmonary neutrophil activity in cystic fibrosis using radiolabeled fluorodeoxyglucose and PET imaging
Related Studies:
Other Cystic Fibrosis Clinical Trials
Other Pennsylvania Clinical Trials
Other Philadelphia Clinical Trials
A Pilot Trial of Phenylbutyrate/Genistein Duotherapy (for Cystic Fibrosis)
|
|
|
|
|
|
|
|
